Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
CAR-T Meeting 2022
Great catching up with @FadiHaddad_MD today - from early data on the novel BCR::ABL1 inhibitor ELVN-001 to practical tolerability strategies for CML in real-world and LMIC settings.
#CMLsm #LEUsm #HemOnc #SOHO2026
Great to speak with @niravshahmd today! He walked us through the key points from his two posters on zamto-cel.
#LymSm #HemOnc #Lymphoma #SOHO2026 @MedicalCollege
Enjoyed sitting down with Giada Bianchi to discuss what the all-cause mortality benefit seen with anselamimab - which targets circulating amyloidogenic light chains rather than the plasma cell clone - tells us about what's really driving AL amyloidosis mortality.
#Amyloidosis
Great to speak with Paolo Neri today! She shared her practical decision tree for community hematologists choosing between BCMA- and GPRC5D-directed T-cell engagers, based on mutations and surface antigen expression rather than line of therapy alone.
#MMsm #HemOnc #Myeloma
Wide-ranging conversation with @doctorpemm today - from his DISC-3405 poster in polycythemia vera to individualizing treatment in myelofibrosis and the full TRANSFORM-1 data.
#MPNsm #HemOnc #Myelofibrosis #SOHO2026 @UTMDAnderson
CAR-T Meeting 2022
Great catching up with @FadiHaddad_MD today - from early data on the novel BCR::ABL1 inhibitor ELVN-001 to practical tolerability strategies for CML in real-world and LMIC settings.
#CMLsm #LEUsm #HemOnc #SOHO2026
Great to speak with @niravshahmd today! He walked us through the key points from his two posters on zamto-cel.
#LymSm #HemOnc #Lymphoma #SOHO2026 @MedicalCollege
Enjoyed sitting down with Giada Bianchi to discuss what the all-cause mortality benefit seen with anselamimab - which targets circulating amyloidogenic light chains rather than the plasma cell clone - tells us about what's really driving AL amyloidosis mortality.
#Amyloidosis
Great to speak with Paolo Neri today! She shared her practical decision tree for community hematologists choosing between BCMA- and GPRC5D-directed T-cell engagers, based on mutations and surface antigen expression rather than line of therapy alone.
#MMsm #HemOnc #Myeloma
Wide-ranging conversation with @doctorpemm today - from his DISC-3405 poster in polycythemia vera to individualizing treatment in myelofibrosis and the full TRANSFORM-1 data.
#MPNsm #HemOnc #Myelofibrosis #SOHO2026 @UTMDAnderson
